Urteste SA (URT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Urteste SA (URT) has a cash flow conversion efficiency ratio of -0.182x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-4.33 Million ≈ $-1.19 Million USD) by net assets (zł23.79 Million ≈ $6.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See URT equity to assets ratio to measure how much of total assets are equity-financed.
Urteste SA - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Urteste SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check URT capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Urteste SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Urteste SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GLORY HEALTH IND. HD-001
F:84R
|
N/A |
|
Artmarket.com SA
PA:PRC
|
0.031x |
|
Volitionrx Ltd
NYSE MKT:VNRX
|
0.154x |
|
Dare Bioscience Inc
NASDAQ:DARE
|
0.508x |
|
UMS Holdings Bhd
KLSE:7137
|
0.018x |
|
Smart Concrete Public Company Limited
BK:SMART
|
0.028x |
|
M VEST WATER NK-00227652
F:7YA
|
-0.105x |
|
Salee Colour Public Company Limited
BK:COLOR
|
0.066x |
Annual Cash Flow Conversion Efficiency for Urteste SA (2019–2025)
The table below shows the annual cash flow conversion efficiency of Urteste SA from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see URT stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | zł24.93 Million ≈ $6.86 Million |
zł10.67 Million ≈ $2.94 Million |
0.428x | +288.70% |
| 2024-12-31 | zł24.11 Million ≈ $6.64 Million |
zł-5.47 Million ≈ $-1.50 Million |
-0.227x | -18.22% |
| 2023-12-31 | zł27.74 Million ≈ $7.64 Million |
zł-5.32 Million ≈ $-1.46 Million |
-0.192x | +71.57% |
| 2022-12-31 | zł5.62 Million ≈ $1.55 Million |
zł-3.79 Million ≈ $-1.04 Million |
-0.675x | -154.05% |
| 2021-12-31 | zł9.69 Million ≈ $2.67 Million |
zł-2.57 Million ≈ $-708.19K |
-0.266x | +73.22% |
| 2020-12-31 | zł1.37 Million ≈ $375.68K |
zł-1.35 Million ≈ $-372.56K |
-0.992x | -197.46% |
| 2019-12-31 | zł1.20 Million ≈ $328.95K |
zł-398.48K ≈ $-109.67K |
-0.333x | -- |
About Urteste SA
Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, bile ducts, stomach, lung, esophagus, ovary, endometrium, blood, breast, and brain. The company was incorporated in 2021 and is based in Gdansk, Poland.